시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 가역성 기도 질환 치료 시장 보고서(2025년)
Reversible Airway Diseases Treatment Global Market Report 2025
상품코드 : 1825536
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가역성 기도 질환 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 6.9%로 1,187억 6,000만 달러로 성장합니다. 예측 기간의 성장은 인구 고령화, 만성질환 유병률 증가, 도시화 및 대기오염 증가, 의료 서비스 접근성 확대에 기인합니다. 예측 기간의 주요 동향으로는 디지털 헬스 기술, 새로운 치료법 연구 및 개발, 조기 개입 및 예방, 흡입기 기술 발전 등이 있습니다.

향후 5년간 6.9%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 인도와 네덜란드에서 조달하는 분무기 및 기관지확장제 흡입기의 비용을 상승시켜 천식 및 COPD 증상 완화를 지연시키고 호흡기과 지출을 증가시킴으로써 미국을 방해할 것으로 예측됩니다. 또한 상호 관세와 무역 긴장의 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 느껴질 것으로 보입니다.

만성 호흡기 질환의 유병률 증가는 향후 수년간 가역적 호흡기 질환 치료 시장의 성장을 가속할 것으로 예측됩니다. 호흡기 질환은 폐, 기관지, 기관, 후두, 인두, 비강을 포함한 호흡기 계통에 영향을 미치는 질환입니다. 만성 호흡기 질환의 검사 및 치료를 통해 급성호흡곤란증후군 등의 조기 발견 및 진단이 가능하며, 합병증 위험을 감소시켜 진행을 예방할 수 있습니다. 예를 들어 2024년 2월 영국 정부 기관인 UK Health Security Agency는 2022-2023년 영국내 결핵 환자가 10.7% 증가하여 4,380명에서 4,850명으로 늘어났다고 보고했습니다. 이는 1년 사이 결핵 발병률이 크게 증가했음을 의미합니다. 그 결과, 만성 호흡기 질환 증가는 가역적 호흡기 질환 치료 시장의 확대를 촉진할 것으로 예측됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $85.53 billion in 2024 to $90.91 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $118.76 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of nebulizers and bronchodilator inhalers sourced from India and the Netherlands, thereby delaying asthma/COPD symptom relief and elevating pulmonology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market in the coming years. Respiratory diseases are conditions impacting the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Testing and treatment for chronic respiratory diseases enable early detection and diagnosis of conditions such as acute respiratory distress syndrome, helping to prevent progression by reducing the risk of complications. For example, in February 2024, the UK Health Security Agency, a government agency in the United Kingdom, reported a 10.7% increase in tuberculosis (TB) cases in England from 2022 to 2023, rising from 4,380 cases to 4,850. This represents a significant increase in TB incidence over the year. Consequently, the rise in chronic respiratory diseases is expected to fuel the expansion of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

Leading companies in the reversible airway disease treatment market are increasingly focusing on inhalational dosage forms in respiratory drug delivery to maintain their market position. For example, in May 2022, Alkem, a pharmaceutical company based in India, launched the Innohaler, a dry powder inhaler (DPI) device. This device is designed to improve life for patients with asthma and COPD by addressing significant gaps in asthma care within India. With the Innohaler, Alkem is stepping into the core inhalation therapeutics market, ensuring that each dose reaches the lungs efficiently. Furthermore, the device is supported by programs promoting patient awareness and adherence, maximizing its impact.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major companies operating in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited.

North America was the largest region in the reversible airway diseases treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Reversible Airway Diseases Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for reversible airway diseases treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The reversible airway diseases treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Reversible Airway Diseases Treatment Growth Analysis And Strategic Analysis Framework

6. Reversible Airway Diseases Treatment Market Segmentation

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

8. Asia-Pacific Reversible Airway Diseases Treatment Market

9. China Reversible Airway Diseases Treatment Market

10. India Reversible Airway Diseases Treatment Market

11. Japan Reversible Airway Diseases Treatment Market

12. Australia Reversible Airway Diseases Treatment Market

13. Indonesia Reversible Airway Diseases Treatment Market

14. South Korea Reversible Airway Diseases Treatment Market

15. Western Europe Reversible Airway Diseases Treatment Market

16. UK Reversible Airway Diseases Treatment Market

17. Germany Reversible Airway Diseases Treatment Market

18. France Reversible Airway Diseases Treatment Market

19. Italy Reversible Airway Diseases Treatment Market

20. Spain Reversible Airway Diseases Treatment Market

21. Eastern Europe Reversible Airway Diseases Treatment Market

22. Russia Reversible Airway Diseases Treatment Market

23. North America Reversible Airway Diseases Treatment Market

24. USA Reversible Airway Diseases Treatment Market

25. Canada Reversible Airway Diseases Treatment Market

26. South America Reversible Airway Diseases Treatment Market

27. Brazil Reversible Airway Diseases Treatment Market

28. Middle East Reversible Airway Diseases Treatment Market

29. Africa Reversible Airway Diseases Treatment Market

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

34. Recent Developments In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기